Introduction Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity
and mortality. A comprehensive description of the global burden of MM is needed to help …

The main obstacle of multiple myeloma (MM) therapy is the compromised immune
microenvironment, which leads to MM relapses and extramedullary disease progression. In …

Background Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence
cases leukaemia, lymphoma, and multiple myeloma in 2020. Identifying its geographical …

Palliative care (PC) has continued to be less available, underutilized, and unintegrated in
many of the healthcare systems, especially in Africa. This scoping review synthesized …

Background Multiple myeloma is a bone marrow‐based hematological malignancy
accounting for approximately two per cent of cancers. First‐line treatment for transplant …

Background Multiple myeloma is a hematological malignancy of plasma cells belonging to a
spectrum of monoclonal protein-secreting disorders known as paraproteinemias. It is …

Background It is known that one of the reasons for the increased incidence of hematological
malignancies is caused by the growth of multiple myeloma (MM). Worldwide, approximately …

Prescription drug affordability is a growing health policy concern. In 2019, pharmaceutical
spending accounted for an estimated 12.6% of overall health spending in the United States …

Multiple myeloma (MM) is a B-cell malignancy characterized by clonal proliferation of
terminally differentiated B lymphocytes. Rational use of proteasome inhibitors …

Multiple myeloma (MM) is one of the commonest hematological malignancies of public
health importance especially in low-income countries (LICs) of Sub-Saharan Africa. The two …